Molecular basis of cancer chemoresistance: biochemical insights

Rasha A Guneidy1

  • 1Department of Molecular Biology, Biotechnology Research Institute, National Research Centre, Cairo Governorate, Egypt.

Drug Metabolism Reviews
|January 26, 2026
PubMed

Insights

Chemoresistance, a major hurdle in cancer treatment, stems from complex genetic and non-genetic factors. Understanding drug metabolism and the tumor microenvironment (TME) is key to developing new therapies.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Chemoresistance significantly limits cancer treatment efficacy and patient survival.
  • It involves diverse mechanisms including genetic mutations, epigenetic changes, and tumor microenvironment (TME) interactions.
  • Recent research (2020-present) has expanded our understanding of these complex resistance pathways.

Purpose of the Study:

  • To review and integrate foundational knowledge with recent advancements in chemoresistance.
  • To emphasize the role of drug-metabolizing enzymes and TME signaling in therapeutic failure.
  • To evaluate strategies for overcoming chemoresistance.

Main Methods:

  • Literature review synthesizing established concepts and recent findings (2020-present).
  • Focus on biochemical mechanisms, epigenetic reprogramming, metabolic alterations, and TME influences.
  • Evaluation of current and emerging therapeutic strategies.

Main Results:

  • Chemoresistance involves altered drug accumulation, metabolism, DNA repair, cell cycle control, and apoptosis evasion.
  • Epigenetic reprogramming, metabolic shifts, and TME signaling are critical in amplifying resistance.
  • Drug-metabolizing enzymes play a significant role in treatment failure.

Conclusions:

  • Targeting metabolic enzymes, modulating the TME, and employing polytherapies are promising strategies.
  • Integrating recent discoveries with existing knowledge is crucial for improving cancer treatment efficacy.
  • Enhanced understanding of chemoresistance mechanisms offers new avenues for better patient outcomes.